BrainCheck

BrainCheck operates at the intersection of digital diagnostics, clinical decision support, remote patient monitoring, and cognitive care management. Its differentiation is breadth: the platform combines screening, formal assessment, interpretation, longitudinal monitoring, care planning, and research workflows rather than focusing only on a single cognitive test. BrainCheck Assess is described as an FDA Class II digital assessment covering five cognitive domains in approximately 15 minutes, while BrainCheck Screen supports a shorter three-to-five-minute prescreening workflow. BrainCheck Plan extends the product beyond measurement into documented, individualized care protocols. The company also supports remote and in-clinic deployment, which broadens its addressable use cases across primary care, specialty care, research, and non-clinical settings. Relative to narrower screening products, BrainCheck’s reported 24-screener portfolio, care-planning capabilities, and research infrastructure suggest a platform-oriented position. Its $54.745 million in cumulative funding, 16 reported investors, HITRUST certification, and growing practice adoption indicate meaningful institutional traction, although private-company valuation and market-share data are unavailable.

BrainCheck’s trajectory shows a shift from early cognitive-assessment development toward a broader care-delivery and research platform. The company raised $3 million in seed funding in 2016, followed by additional seed rounds in 2017 and 2018 and an $8 million Series A in 2019. It then added a $10 million Series B in 2021, a $15 million venture round in 2024, grants totaling $2 million in 2022 and 2025, and a $13 million Series A announced on Feb 26, 2026. The funding history indicates sustained capital formation, although the naming of the 2026 round differs from earlier round labels. Product expansion has been visible: six screeners launched during 2025, taking the total to 24, while the November 2024 launch with Synaps Dx and Clarity Health Clinics extended access to at-home Alzheimer’s and cognitive-health screening. Commercial adoption also accelerated, with 150 practices joining in 2025 and 240 additional clinics reported as adopting the platform in 2024. Leadership additions support this scale-up: Steve Wardle joined as President in July 2025, while product and operations executives were added during the same period. Research publications and 2026 conference activity provide another growth vector beyond routine clinical screening.